AM3 inhibits LPS-induced iNOS expression in mice
We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expressio...
Gespeichert in:
Veröffentlicht in: | International immunopharmacology 2005-07, Vol.5 (7), p.1165-1170 |
---|---|
Hauptverfasser: | , , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 1170 |
---|---|
container_issue | 7 |
container_start_page | 1165 |
container_title | International immunopharmacology |
container_volume | 5 |
creator | Majano, Pedro Alonso-Lebrero, José Luis Janczyk, Agnieszka Martín-Vichez, Samuel Molina-Jiménez, Francisca Brieva, Aurora Pivel, Juan Pablo González, Salvador López-Cabrera, Manuel Moreno-Otero, Ricardo |
description | We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response. |
doi_str_mv | 10.1016/j.intimp.2005.02.009 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_67868345</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1567576905000524</els_id><sourcerecordid>67868345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</originalsourceid><addsrcrecordid>eNqFkE1Lw0AQhhdRbK3-A5Fc9JY4-5nsRZDiF1QrVM9Lspniliapu6nov3dLC73paYbheV-Gh5BzChkFqq4XmWt716wyBiAzYBmAPiBDWuRFSnOQh3GXKk9lrvSAnISwAIh3QY_JgEpNBWd0SOD2mSeu_XCV60MyeZ2lrq3XFuvEvUxnCX6vPIbgujZCSeMsnpKjebkMeLabI_J-f_c2fkwn04en8e0ktZyrPmXWal2IqmIVlAAF15RzyWTBKqahZJzV81qAZhrRCia54sArxnLFUTAFfESutr0r332uMfSmccHiclm22K2DUXmhCi7kvyDNhdRa5xEUW9D6LgSPc7Pyrin9j6FgNkrNwmyVmo1SA8xEpTF2setfVw3W-9DOYQQud0AZbLmc-7K1Luw5VVABdPPozZbDqO3LoTfBOmyja-fR9qbu3N-f_AIPc5JT</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>17459997</pqid></control><display><type>article</type><title>AM3 inhibits LPS-induced iNOS expression in mice</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Majano, Pedro ; Alonso-Lebrero, José Luis ; Janczyk, Agnieszka ; Martín-Vichez, Samuel ; Molina-Jiménez, Francisca ; Brieva, Aurora ; Pivel, Juan Pablo ; González, Salvador ; López-Cabrera, Manuel ; Moreno-Otero, Ricardo</creator><creatorcontrib>Majano, Pedro ; Alonso-Lebrero, José Luis ; Janczyk, Agnieszka ; Martín-Vichez, Samuel ; Molina-Jiménez, Francisca ; Brieva, Aurora ; Pivel, Juan Pablo ; González, Salvador ; López-Cabrera, Manuel ; Moreno-Otero, Ricardo</creatorcontrib><description>We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.</description><identifier>ISSN: 1567-5769</identifier><identifier>EISSN: 1878-1705</identifier><identifier>DOI: 10.1016/j.intimp.2005.02.009</identifier><identifier>PMID: 15914321</identifier><language>eng</language><publisher>Amsterdam: Elsevier B.V</publisher><subject>AM3 ; Animals ; Anti-Inflammatory Agents - pharmacology ; Anti-inflammatory response ; Biological and medical sciences ; Calcium Phosphates - pharmacology ; Female ; Gene Expression - drug effects ; Glycopeptides - pharmacology ; Inmunoferon ; iNOS ; Lipopolysaccharides - antagonists & inhibitors ; Male ; Medical sciences ; Mice ; Mice, Inbred BALB C ; Nitric oxide ; Nitric Oxide - biosynthesis ; Nitric Oxide Synthase - genetics ; Nitric Oxide Synthase Type II ; Pharmacology. Drug treatments ; Rats ; Rats, Inbred Lew ; Tumor Necrosis Factor-alpha - biosynthesis</subject><ispartof>International immunopharmacology, 2005-07, Vol.5 (7), p.1165-1170</ispartof><rights>2005 Elsevier B.V.</rights><rights>2005 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</citedby><cites>FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.intimp.2005.02.009$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=16814015$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15914321$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Majano, Pedro</creatorcontrib><creatorcontrib>Alonso-Lebrero, José Luis</creatorcontrib><creatorcontrib>Janczyk, Agnieszka</creatorcontrib><creatorcontrib>Martín-Vichez, Samuel</creatorcontrib><creatorcontrib>Molina-Jiménez, Francisca</creatorcontrib><creatorcontrib>Brieva, Aurora</creatorcontrib><creatorcontrib>Pivel, Juan Pablo</creatorcontrib><creatorcontrib>González, Salvador</creatorcontrib><creatorcontrib>López-Cabrera, Manuel</creatorcontrib><creatorcontrib>Moreno-Otero, Ricardo</creatorcontrib><title>AM3 inhibits LPS-induced iNOS expression in mice</title><title>International immunopharmacology</title><addtitle>Int Immunopharmacol</addtitle><description>We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.</description><subject>AM3</subject><subject>Animals</subject><subject>Anti-Inflammatory Agents - pharmacology</subject><subject>Anti-inflammatory response</subject><subject>Biological and medical sciences</subject><subject>Calcium Phosphates - pharmacology</subject><subject>Female</subject><subject>Gene Expression - drug effects</subject><subject>Glycopeptides - pharmacology</subject><subject>Inmunoferon</subject><subject>iNOS</subject><subject>Lipopolysaccharides - antagonists & inhibitors</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Mice</subject><subject>Mice, Inbred BALB C</subject><subject>Nitric oxide</subject><subject>Nitric Oxide - biosynthesis</subject><subject>Nitric Oxide Synthase - genetics</subject><subject>Nitric Oxide Synthase Type II</subject><subject>Pharmacology. Drug treatments</subject><subject>Rats</subject><subject>Rats, Inbred Lew</subject><subject>Tumor Necrosis Factor-alpha - biosynthesis</subject><issn>1567-5769</issn><issn>1878-1705</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1Lw0AQhhdRbK3-A5Fc9JY4-5nsRZDiF1QrVM9Lspniliapu6nov3dLC73paYbheV-Gh5BzChkFqq4XmWt716wyBiAzYBmAPiBDWuRFSnOQh3GXKk9lrvSAnISwAIh3QY_JgEpNBWd0SOD2mSeu_XCV60MyeZ2lrq3XFuvEvUxnCX6vPIbgujZCSeMsnpKjebkMeLabI_J-f_c2fkwn04en8e0ktZyrPmXWal2IqmIVlAAF15RzyWTBKqahZJzV81qAZhrRCia54sArxnLFUTAFfESutr0r332uMfSmccHiclm22K2DUXmhCi7kvyDNhdRa5xEUW9D6LgSPc7Pyrin9j6FgNkrNwmyVmo1SA8xEpTF2setfVw3W-9DOYQQud0AZbLmc-7K1Luw5VVABdPPozZbDqO3LoTfBOmyja-fR9qbu3N-f_AIPc5JT</recordid><startdate>200507</startdate><enddate>200507</enddate><creator>Majano, Pedro</creator><creator>Alonso-Lebrero, José Luis</creator><creator>Janczyk, Agnieszka</creator><creator>Martín-Vichez, Samuel</creator><creator>Molina-Jiménez, Francisca</creator><creator>Brieva, Aurora</creator><creator>Pivel, Juan Pablo</creator><creator>González, Salvador</creator><creator>López-Cabrera, Manuel</creator><creator>Moreno-Otero, Ricardo</creator><general>Elsevier B.V</general><general>Elsevier</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>7X8</scope></search><sort><creationdate>200507</creationdate><title>AM3 inhibits LPS-induced iNOS expression in mice</title><author>Majano, Pedro ; Alonso-Lebrero, José Luis ; Janczyk, Agnieszka ; Martín-Vichez, Samuel ; Molina-Jiménez, Francisca ; Brieva, Aurora ; Pivel, Juan Pablo ; González, Salvador ; López-Cabrera, Manuel ; Moreno-Otero, Ricardo</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c336t-2cc9984bb2b0a0083913352582b290a232dfd40929eec42536303b22763e42603</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>AM3</topic><topic>Animals</topic><topic>Anti-Inflammatory Agents - pharmacology</topic><topic>Anti-inflammatory response</topic><topic>Biological and medical sciences</topic><topic>Calcium Phosphates - pharmacology</topic><topic>Female</topic><topic>Gene Expression - drug effects</topic><topic>Glycopeptides - pharmacology</topic><topic>Inmunoferon</topic><topic>iNOS</topic><topic>Lipopolysaccharides - antagonists & inhibitors</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Mice</topic><topic>Mice, Inbred BALB C</topic><topic>Nitric oxide</topic><topic>Nitric Oxide - biosynthesis</topic><topic>Nitric Oxide Synthase - genetics</topic><topic>Nitric Oxide Synthase Type II</topic><topic>Pharmacology. Drug treatments</topic><topic>Rats</topic><topic>Rats, Inbred Lew</topic><topic>Tumor Necrosis Factor-alpha - biosynthesis</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Majano, Pedro</creatorcontrib><creatorcontrib>Alonso-Lebrero, José Luis</creatorcontrib><creatorcontrib>Janczyk, Agnieszka</creatorcontrib><creatorcontrib>Martín-Vichez, Samuel</creatorcontrib><creatorcontrib>Molina-Jiménez, Francisca</creatorcontrib><creatorcontrib>Brieva, Aurora</creatorcontrib><creatorcontrib>Pivel, Juan Pablo</creatorcontrib><creatorcontrib>González, Salvador</creatorcontrib><creatorcontrib>López-Cabrera, Manuel</creatorcontrib><creatorcontrib>Moreno-Otero, Ricardo</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>International immunopharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Majano, Pedro</au><au>Alonso-Lebrero, José Luis</au><au>Janczyk, Agnieszka</au><au>Martín-Vichez, Samuel</au><au>Molina-Jiménez, Francisca</au><au>Brieva, Aurora</au><au>Pivel, Juan Pablo</au><au>González, Salvador</au><au>López-Cabrera, Manuel</au><au>Moreno-Otero, Ricardo</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>AM3 inhibits LPS-induced iNOS expression in mice</atitle><jtitle>International immunopharmacology</jtitle><addtitle>Int Immunopharmacol</addtitle><date>2005-07</date><risdate>2005</risdate><volume>5</volume><issue>7</issue><spage>1165</spage><epage>1170</epage><pages>1165-1170</pages><issn>1567-5769</issn><eissn>1878-1705</eissn><abstract>We have analyzed the effect of a patented glycoconjugate of natural origin, AM3 (commercially available under the name Inmunoferon®) in the expression of iNOS induced by administration of LPS in mice. We have observed that oral treatment with the drug daily for 6 days reduced the levels of expression of iNOS induced by an intravenous pulse of LPS. This effect was significant in the lungs and kidneys, but it was much more marked in the liver. In addition, the levels of nitric oxide in serum were clearly decreased upon treatment with AM3. Together, these results suggest that AM3 modulates the nitric oxide response and points to a possible role for AM3 in the control of the inflammatory response.</abstract><cop>Amsterdam</cop><pub>Elsevier B.V</pub><pmid>15914321</pmid><doi>10.1016/j.intimp.2005.02.009</doi><tpages>6</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1567-5769 |
ispartof | International immunopharmacology, 2005-07, Vol.5 (7), p.1165-1170 |
issn | 1567-5769 1878-1705 |
language | eng |
recordid | cdi_proquest_miscellaneous_67868345 |
source | MEDLINE; Access via ScienceDirect (Elsevier) |
subjects | AM3 Animals Anti-Inflammatory Agents - pharmacology Anti-inflammatory response Biological and medical sciences Calcium Phosphates - pharmacology Female Gene Expression - drug effects Glycopeptides - pharmacology Inmunoferon iNOS Lipopolysaccharides - antagonists & inhibitors Male Medical sciences Mice Mice, Inbred BALB C Nitric oxide Nitric Oxide - biosynthesis Nitric Oxide Synthase - genetics Nitric Oxide Synthase Type II Pharmacology. Drug treatments Rats Rats, Inbred Lew Tumor Necrosis Factor-alpha - biosynthesis |
title | AM3 inhibits LPS-induced iNOS expression in mice |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T09%3A07%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=AM3%20inhibits%20LPS-induced%20iNOS%20expression%20in%20mice&rft.jtitle=International%20immunopharmacology&rft.au=Majano,%20Pedro&rft.date=2005-07&rft.volume=5&rft.issue=7&rft.spage=1165&rft.epage=1170&rft.pages=1165-1170&rft.issn=1567-5769&rft.eissn=1878-1705&rft_id=info:doi/10.1016/j.intimp.2005.02.009&rft_dat=%3Cproquest_cross%3E67868345%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=17459997&rft_id=info:pmid/15914321&rft_els_id=S1567576905000524&rfr_iscdi=true |